查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1347531

潰瘍性結腸炎市場：2023-2028 年全球行業趨勢、佔有率、規模、成長、機會和預測

Ulcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

市場概況：

2022年，全球潰瘍性結腸炎市場規模達到74億美元。展望未來，IMARC Group預計到2028年市場規模將達到102億美元，2023-2028年年複合成長率（CAGR）為5.4%。

潰瘍性結腸炎 (UC) 是一種慢性炎症性腸病 (IBD)，會引起消化道刺激、炎症和潰瘍（瘡）。它通常影響大腸（或結腸）和直腸的內壁。這些症狀通常會隨著時間的推移而出現，被診斷為 UC 的個體可能會經歷輕微症狀或無症狀的時期。然而，它有時會導致衰弱或危及生命的併發症。雖然 UC 尚無法治愈，但治療可以幫助患者控制和減輕症狀、預防病情發作並實現長期緩解。因此，UC 治療在全球範圍內迅速受到關注，因為它有助於提高生活品質並確保患者的身心健康。

潰瘍性結腸炎市場趨勢：

UC 疾病的廣泛流行和對可用治療方案的認知不斷提高是推動市場成長的主要因素。除此之外，強大的管道產品的存在和眾多藥物的不斷進步正在增加產品需求。此外，各國政府正在採取多項舉措來提高人們對這種疾病的認知，並提高適當醫療設施的可及性和可用性。這與開發新療法的研發（R＆D）活動的投資不斷增加相結合，正在推動市場成長。此外，領先企業正致力於推出創新和更有效的藥物，以擴大其產品組合併在市場上獲得競爭優勢。其他因素，包括生物學名藥的容易獲得、醫療基礎設施的改善、有利的報銷政策以及消費者在醫療保健方面的支出增加，也創造了積極的市場前景。

本報告回答的關鍵問題：

  • 迄今為止，全球潰瘍性結腸炎市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球潰瘍性結腸炎市場有何影響？
  • 主要區域市場有哪些？
  • 根據類型分類市場是怎樣的？
  • 根據疾病類型的市場分類是怎樣的？
  • 根據分子類型的市場細分是什麼？
  • 根據藥物類型分類的市場是怎樣的？
  • 根據給藥途徑，市場的分化是什麼？
  • 基於配銷通路的市場細分是什麼？
  • 行業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球潰瘍性結腸炎市場的結構如何？誰是主要參與者？
  • 行業競爭程度如何？

目錄

第一章：前言

第 2 章：範圍和方法

  • 研究目的
  • 利益相關者
  • 數據源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球潰瘍性結腸炎市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按類型分類的市場細分

  • 輕度UC
    • 市場走向
    • 市場預測
  • 中度UC
    • 市場走向
    • 市場預測
  • 嚴重潰瘍性結腸炎
    • 市場走向
    • 市場預測

第 7 章：按疾病類型分類的市場

  • 潰瘍性直腸炎
    • 市場走向
    • 市場預測
  • 直腸乙狀結腸炎
    • 市場走向
    • 市場預測
  • 左側結腸炎
    • 市場走向
    • 市場預測
  • 全結腸炎或普遍性結腸炎
    • 市場走向
    • 市場預測
  • 暴發性結腸炎
    • 市場走向
    • 市場預測

第 8 章：按分子類型分類的市場

  • 小分子
    • 市場走向
    • 市場預測
  • 生物製劑
    • 市場走向
    • 市場預測

第 9 章：按藥物類型分類的市場細分

  • 抗發炎藥
    • 市場走向
    • 市場預測
  • 抗腫瘤壞死因子生物製劑
    • 市場走向
    • 市場預測
  • 免疫抑製劑
    • 市場走向
    • 市場預測
  • 鈣調磷酸酶抑製劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 10 章：按管理途徑分類的市場

  • 口服
    • 市場走向
    • 市場預測
  • 可注射
    • 市場走向
    • 市場預測

第 11 章：按配銷通路分類的市場細分

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥店
    • 市場走向
    • 市場預測
  • 藥店
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 12 章：按地區分類的市場細分

  • 北美
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳大利亞
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 13 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 14 章：價值鏈分析

第 15 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 16 章：價格分析

第17章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112023A5663

Market Overview:

The global ulcerative colitis market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2023-2028.

Ulcerative colitis (UC) refers to a chronic inflammatory bowel disease (IBD) that causes irritation, inflammation, and ulcers (sores) in the digestive tract. It typically affects the inner lining of the large intestine (or colon) and rectum. The symptoms generally develop over time, and individuals diagnosed with UC may experience periods of mild or no symptoms. However, it can sometimes lead to debilitating or life-threatening complications. While there is no cure for UC yet, the treatment can help patients manage and reduce their symptoms, prevent flare-ups, and bring about long-term remission. As a result, UC treatment is rapidly gaining traction across the globe as it can help enhance the quality of life and ensure the physical and mental wellbeing of the patients.

Ulcerative Colitis Market Trends:

The widespread prevalence of UC disease and the rising awareness regarding the available treatment options represent the primary factors driving the market growth. Besides this, the presence of strong pipeline products and continuous advancements in numerous drugs are augmenting the product demand. Additionally, governments of various countries are taking several initiatives to spread awareness about the condition and enhance the accessibility and availability of proper healthcare facilities. This, in confluence with the increasing investments in the research and development (R&D) activities for the development of novel therapies, is propelling the market growth. Furthermore, the leading players are focusing on launching innovative and more effective drugs to expand their product portfolio and gain a competitive edge in the market. Other factors, including the easy availability of biosimilar drugs, improving healthcare infrastructure, favorable reimbursement policies, and increasing consumer spending on healthcare, are also creating a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ulcerative colitis market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, disease type, molecule type, drug type, route of administration and distribution channel.

Breakup by Type:

Mild UC

Moderate UC

Severe UC

Breakup by Disease Type:

Ulcerative Proctitis

Proctosigmoiditis

Left-sided Colitis

Pancolitis or Universal Colitis

Fulminant Colitis

Breakup by Molecule Type:

Small Molecules

Biologics

Breakup by Drug Type:

Anti-Inflammatory Drugs

Anti-TNF Biologics

Immunosuppressant

Calcineurin Inhibitors

Others

Breakup by Route of Administration:

Oral

Injectable

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Store

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global ulcerative colitis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global ulcerative colitis market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the molecule type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global ulcerative colitis market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ulcerative Colitis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Moderate UC
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Severe UC
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Proctosigmoiditis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Left-sided Colitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Fulminant Colitis
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Immunosuppressant
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Injectable
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Store
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Abbott Laboratories
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 AbbVie Inc.
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
      • 17.3.2.4 SWOT Analysis
    • 17.3.3 AstraZeneca plc
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 Financials
      • 17.3.3.4 SWOT Analysis
    • 17.3.4 Bristol-Myers Squibb Company
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
      • 17.3.4.3 Financials
      • 17.3.4.4 SWOT Analysis
    • 17.3.5 Eli Lilly and Company
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 F. Hoffmann-La Roche Ltd.
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
    • 17.3.7 GlaxoSmithKline plc
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 Johnson & Johnson
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 Merck & Co. Inc.
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
      • 17.3.9.3 Financials
      • 17.3.9.4 SWOT Analysis
    • 17.3.10 Pfizer Inc.
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 Financials
      • 17.3.10.4 SWOT Analysis
    • 17.3.11 Takeda Pharmaceutical Company Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis
    • 17.3.12 Teva Pharmaceutical Industries Ltd.
      • 17.3.12.1 Company Overview
      • 17.3.12.2 Product Portfolio
      • 17.3.12.3 Financials
      • 17.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ulcerative Colitis Market: Major Drivers and Challenges
  • Figure 2: Global: Ulcerative Colitis Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Ulcerative Colitis Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Ulcerative Colitis Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Ulcerative Colitis Market: Breakup by Disease Type (in %), 2022
  • Figure 6: Global: Ulcerative Colitis Market: Breakup by Molecule Type (in %), 2022
  • Figure 7: Global: Ulcerative Colitis Market: Breakup by Drug Type (in %), 2022
  • Figure 8: Global: Ulcerative Colitis Market: Breakup by Route of Administration (in %), 2022
  • Figure 9: Global: Ulcerative Colitis Market: Breakup by Distribution Channel (in %), 2022
  • Figure 10: Global: Ulcerative Colitis Market: Breakup by Region (in %), 2022
  • Figure 11: Global: Ulcerative Colitis (Mild UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Ulcerative Colitis (Mild UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Ulcerative Colitis (Moderate UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Ulcerative Colitis (Moderate UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Ulcerative Colitis (Severe UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Ulcerative Colitis (Severe UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Ulcerative Colitis (Ulcerative Proctitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Ulcerative Colitis (Ulcerative Proctitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Ulcerative Colitis (Proctosigmoiditis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Ulcerative Colitis (Proctosigmoiditis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Ulcerative Colitis (Left-sided Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Ulcerative Colitis (Left-sided Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Ulcerative Colitis (Fulminant Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Ulcerative Colitis (Fulminant Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Ulcerative Colitis (Small Molecules) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Ulcerative Colitis (Small Molecules) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Ulcerative Colitis (Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Ulcerative Colitis (Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Ulcerative Colitis (Anti-TNF Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Ulcerative Colitis (Anti-TNF Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Ulcerative Colitis (Immunosuppressant) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Ulcerative Colitis (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Ulcerative Colitis (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Ulcerative Colitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Ulcerative Colitis (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Ulcerative Colitis (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Global: Ulcerative Colitis (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Global: Ulcerative Colitis (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Global: Ulcerative Colitis (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Global: Ulcerative Colitis (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Global: Ulcerative Colitis (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Global: Ulcerative Colitis (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Global: Ulcerative Colitis (Drug Store) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Global: Ulcerative Colitis (Drug Store) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Global: Ulcerative Colitis (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Global: Ulcerative Colitis (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: North America: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: North America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: United States: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: United States: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Canada: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Canada: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Asia-Pacific: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Asia-Pacific: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: China: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: China: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Japan: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Japan: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: India: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: India: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: South Korea: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: South Korea: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Australia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Australia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Indonesia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Indonesia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Europe: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Europe: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Germany: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Germany: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: France: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: France: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: United Kingdom: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: United Kingdom: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Italy: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Italy: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Spain: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Spain: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Russia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Russia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 91: Latin America: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 92: Latin America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 93: Brazil: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 94: Brazil: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 95: Mexico: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 96: Mexico: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 97: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 98: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 99: Middle East and Africa: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 100: Middle East and Africa: Ulcerative Colitis Market: Breakup by Country (in %), 2022
  • Figure 101: Middle East and Africa: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 102: Global: Ulcerative Colitis Industry: SWOT Analysis
  • Figure 103: Global: Ulcerative Colitis Industry: Value Chain Analysis
  • Figure 104: Global: Ulcerative Colitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ulcerative Colitis Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Ulcerative Colitis Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Ulcerative Colitis Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 4: Global: Ulcerative Colitis Market Forecast: Breakup by Molecule Type (in Million US$), 2023-2028
  • Table 5: Global: Ulcerative Colitis Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 6: Global: Ulcerative Colitis Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 7: Global: Ulcerative Colitis Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 8: Global: Ulcerative Colitis Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 9: Global: Ulcerative Colitis Market: Competitive Structure
  • Table 10: Global: Ulcerative Colitis Market: Key Players